COS5 Inhibitors
COS5 Inhibitors encompass a range of chemical compounds that influence the functional activity of COS5 by modulating specific signaling pathways or biological processes. For instance, staurosporine, as a broad kinase inhibitor, can diminish COS5 activity by blocking the phosphorylation of kinases that may be essential for COS5 activation. LY294002 and wortmannin, both PI3K inhibitors, can reduce COS5 activity by inhibiting the PI3K/AKT pathway, which may be necessary for COS5's function. Rapamycin, by inhibiting mTORC1, could suppress COS5 if COS5 is involved in processes governed by mTORC1, such as cell growth and proliferation.
U0126 and PD 98059, as inhibitors of the MEK/ERK pathway, could decrease COS5 activity if COS5 operates within or is regulated by this pathway. SB203580 and SP600125 target the p38 MAPK and JNK pathways, respectively; inhibition of these pathways would result in decreased COS5 activity if COS5 is regulated by stress or inflammatory signaling. PP2 specifically inhibits Src family kinases, potentially leading to decreased COS5 activity if Src kinase signaling activates COS5. Imatinib, by inhibiting ABL and c-KITtyrosine kinases, can impede COS5 activity if COS5 relies on signaling through these kinases. Sorafenib targets RAF kinases within the MAPK pathway; if COS5 is regulated by this pathway, its activity would be reduced by sorafenib. Lastly, bortezomib's role as a proteasome inhibitor could lead to the accumulation of proteins that negatively regulate COS5, thus indirectly inhibiting its activity if COS5 degradation is critical for its function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-specific kinase inhibitor. If COS5 functions are mediated by protein kinase-dependent signaling, staurosporine can inhibit these kinases, leading to a reduction in COS5 activity due to the lack of phosphorylation events that activate COS5 or its associated partners. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that would prevent the phosphorylation and activation of AKT. If COS5 activity is promoted by the PI3K/AKT pathway, the inhibition of this pathway would result in decreased COS5 activity due to the reduced activation of downstream targets that may be necessary for COS5 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that interrupts the mTORC1 pathway. Since mTORC1 is involved in cell growth and proliferation, its inhibition by rapamycin would lead to reduced COS5 activity if COS5 is involved in these cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that blocks the activation of MEK1/2, thus inhibiting the ERK pathway. If COS5 is activated by the ERK pathway or has functional cooperation with it, U0126 would decrease COS5 activity by preventing the activation of this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If COS5's activity is regulated by the p38 MAPK pathway, inhibition of this pathway by SB203580 would lead to a decrease in COS5 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. If COS5 is activated by Src kinase signaling, inhibition of these kinases by PP2 would result in decreased COS5 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a selective inhibitor of certain tyrosine kinases, including ABL and c-KIT. If COS5 is downstream of these kinases, its functional activity could be inhibited by imatinib, leading to decreased COS5 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor targeting RAF kinases, which are part of the MAPK pathway. Inhibition by sorafenib would lead to decreased COS5 activity if COS5 is regulated by the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If COS5 is regulated by JNK signaling, inhibition of JNK by SP600125 would result in decreased COS5 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002, and thus would also lead to decreased COS5 activity if COS5 is dependent on the PI3K/AKT signaling pathway. | ||||||